Project Grant R21HL175174
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $760,374 to National Jewish Health in Denver, Colorado to conduct a multi-year research study on sarcoidosis. The project aims to identify diagnostic and prognostic blood signatures associated with pulmonary sarcoidosis risk and disease progression, integrating clinical data, genetic factors, gene expression, and...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $127,875 Project Grant (R21HL175092) to the Oklahoma Medical Research Foundation (OMRF) for a 2-year period from August 1, 2024 to July 31, 2026. The grant supports a multi-omic characterization of immune cells in sarcoidosis, a complex and heterogeneous systemic disease. The research aims to discover molecular signatures that can improve sarcoidosis...
This $751,954 Project Grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to investigate the use of CXCR3 blockade as a potential precision therapy for cardiac sarcoidosis. The research will utilize single-cell multi-omics and T-cell receptor sequencing techniques to define key pathogenic T-cell subsets and interactions between adaptive and innate immunity that drive cardiac sarcoidosis. It will also explore...
This $827,356 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) will support a prospective multi-parametric imaging study to investigate response to immune suppressant therapy in patients with active cardiac sarcoidosis. The 5-year study will enroll 174 treatment-naïve patients and utilize advanced imaging techniques including cardiac MRI, PET, and perfusion imaging to evaluate imaging...
This federal Project Grant award, valued at $313,632.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a 5-year research project led by Dr. Joseph Cooley at National Jewish Health in Denver, Colorado. The project aims to investigate how interleukin-6 (IL-6) promotes resistance to apoptosis (programmed cell death) in lung fibroblasts, and to explore therapeutic strategies targeting the IL-6-BCL-2...
This federal Project Grant award, with an ID of R56HL173123, was provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The $300,000 award, granted on Sep 24, 2024, supports a research project investigating the role of residential bioaerosol exposure in pulmonary sarcoidosis, a rare systemic inflammatory disease. The primary objectives are to: 1) determine the association between residential bioaerosol exposure and...
This federal Project Grant award, with a total funding amount of $2,323,927.00 over the period of July 15, 2024 to June 30, 2028, was granted by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to understand the mechanisms underlying the emergence and functional role of inflammatory fibroblasts in the development of pulmonary fibrosis. The project aims to utilize single-cell RNA sequencing, lineage...
This $1,546,880 federal Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Pittsburgh focused on understanding the regulation of myofibroblasts, a key cell type involved in the development of pulmonary fibrosis. The research aims to determine the "regulatory architecture" of open chromatin in myofibroblasts, how E-box transcription factors regulate...
This federal Project Grant award of $116,625 from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund a study to characterize novel phenotypes related to osteoporosis and sarcopenia in Chronic Obstructive Pulmonary Disease (COPD). The key products and services to be delivered include: Development and validation of automated CT-based methods to measure static metrics of spine, vertebrae, and pectoral muscles, as well...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $602,955 Project Grant to National Jewish Health to investigate the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active epithelial repair. The primary objectives are to: 1) Determine if a subset of airspace macrophages resembling interstitial macrophages are specialized for...